Neoplasia/BPH

	Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. J Pharmacokinet Pharmacodyn Wang Y, Hadigol M, Lincha VR, Hoffman J, Azad AA, Agarwal N, Matsubara N, Zohren F, DeAnnuntis L, Wang DD. PMID: 42243460 [PubMed - in process]
	Development of ultrasonography for the detection of prostate cancer. J Med Ultrason (2001) Kuroda S, Yuzuriha S, Takahashi K, Naruse J, Nakajima N, Shoji S. PMID: 42243380 [PubMed - as supplied by publisher]
	Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study. Eur Urol Oncol Bresser CC, Garvelink MM, van Dijk T, van der Linde N, van den Berg BMM, Dolk FCK, van Melick HHE, van der Nat PB, SDM-RCC Study Group. PMID: 42242942 [PubMed - as supplied by publisher]
	Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study. Eur Urol Oncol Mandel PC, Wenzel M, Gandur Quiroga MN, Bourlon MT, Chun F, Myint ZW, Bernal L, Kopp RM, Juan Fita MJ, Büttner T, Fiala O, Li H, Bögemann M, Buchler T, Matthews D, Rizzo A, Ciccimarra F, Marques Monteiro FS, Soares A, Massari F, Steuber T, Santoni M. PMID: 42242941 [PubMed - as supplied by publisher]
	Reply to Selcuk Guven, Selim Soyturk, and Thomas Herrmann's Letter to the Editor re: Jeremy Y. Teoh, Francesco M. Bracco, Julius H. Wong, et al. A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial. Eur Urol Oncol 2026;86:111-15: My Vision for the Novel Transurethral Robotic Platform. Eur Urol Oncol Teoh JY. PMID: 42242940 [PubMed - as supplied by publisher]
	Sequential Imaging of Suspicion of Prostate Cancer: Reducing Overdiagnosis and Unnecessary Biopsy with Timely Diagnosis of Significant Cancer (SPROUT)-Prospective Multicentre Cohort Study Protocol. Eur Urol Oncol Sweere V, de Rooij M, Kil PJM, Israel B, van Basten JPA, Boellaard TN, Graus SA, van der Heijden AG, van der Hoeven EJRJ, Klaver OS, Mertens LS, Prette JF, Roelofs LAJ, Sedelaar JPM, Snoek AM, Somford DM, Barentsz JO, Van Melick HHE, van den Bergh RCN. PMID: 42242939 [PubMed - as supplied by publisher]
	Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing (68)Ga-PSMA PET/CT. J Nucl Med Jia KY, Kuten J, Jia HY, Bent EH, Silveira P, Pasquini L, Nalavenkata S, Schoder H, Fox JJ, Yeh R, Razmaria AA. PMID: 42242869 [PubMed - as supplied by publisher]
	Transition Zone PSA Density Does Not Improve Detection of Clinically Significant Prostate Cancer Over Whole-Gland PSAD: A Volume-Stratified Analysis in 3,958 Patients. Urol Int Behnel N, Engelage L, Lumiani A, Buchner A, Stadelmeier LF, Sroka R, Tamalunas A. PMID: 42241366 [PubMed - as supplied by publisher]
	Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate and High-Risk Prostate Cancer. Urol Int Albarghouth MH, Leeder M, Leucht K, Seifert P, Freesmeyer M, Hakenberg OW, Grimm MO. PMID: 42241365 [PubMed - as supplied by publisher]
	Intravoxel incoherent motion diffusion-weighted imaging for early response stratification of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor in renal cell carcinoma: an exploratory study. Jpn J Radiol Kang H, Zhao J, Ding X, Li S, Xie L, Yu M, Wen X, Zhou S, Bai X, Wang Y, Liang Q, Peng C, Huang Q, Gu L, Wang H. PMID: 42240729 [PubMed - as supplied by publisher]
	Early vs. delayed primary local therapy and survival in de novo metastatic prostate cancer: target trial emulation. World J Urol Hassan AA, Aboelsaad AY, Gawad AMA, El-Dydamony EM, Algammal MI, Abdel-Al I, Koritenah AK, Abuelazayem TM, Salman MF, El-Wahsh AF, Ali MM, Shouman HA, Hindawy MA, Deif H, Wasfy IS. PMID: 42240667 [PubMed - in process]
	Image-guided percutaneous ablation techniques for the treatment of renal cell carcinoma: a primer for radiologists. Abdom Radiol (NY) Hernández-Mancera J, Remer EM, Graumann O, Borgbjerg J. PMID: 42240648 [PubMed - as supplied by publisher]
	Deep learning for clinically significant prostate cancer detection on MRI: a systematic review, HSROC meta-analysis, and direct comparison with PI-RADS-based interpretation. Abdom Radiol (NY) Gete KY, Ayele AA. PMID: 42240646 [PubMed - as supplied by publisher]
	Prostate Cancer Staging MRI: Prospective Value of Structured Reports With Defined Extraprostatic Extension Grading System. J Comput Assist Tomogr Huang YH, Ozutemiz A, Mason A, Zhang L, Murugan P, Regmi S, Spilseth B. PMID: 42240110 [PubMed - as supplied by publisher]
	Sarcopenia Weakens the Benefit of Bacillus Calmette-GuÃ©rin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study. Int J Urol Nishimura N, Miyake M, Iwao T, Oda Y, Shimizu T, Owari T, Iida K, Tomizawa M, Onishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Tanaka N, Fujimoto K. PMID: 42240105 [PubMed - in process]
	Evaluation of kidney stone-related renal infection status by 18F-FDG PET/CT in lung cancer patients with concomitant nephrolithiasis: a multicenter study. Front Immunol Yao X, Ying X, Liu H, Duan C, Li B, Hao Z, Ye Z, Xu H, Mei H, Liu H, Liu J. PMID: 42238574 [PubMed - indexed for MEDLINE]
	Transcriptome-wide association study of prostate cancer in the Chinese population. Asian J Urol Hu W, Zeng X, Zhang J, Ruan X, Zhan Y, Yao C, Xin X, Chen H, Na R. PMID: 42238340 [PubMed]
	Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naÃ¯ve primary prostate cancer. Asian J Urol Li X, Song J, Yao X, Zhao Z, Zhang Q, Li R, Zhang P, Wu W, Sun H, Ai S, Yang F, Guo H, Shi K, Afshar-Oromieh A, Zhang L, Lu G, Civelek AC, Wang F. PMID: 42238338 [PubMed]
	Artificial Intelligence as a Diagnostic Tool for Benign Prostatic Hyperplasia (BPH): A Narrative Review. Res Rep Urol Aljazei E. PMID: 42237984 [PubMed]
	A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes. Future Oncol Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Laird AD, Kennedy D, Agarwal N. PMID: 42237765 [PubMed - as supplied by publisher]

Articles 1 - 20 / 188349

Page 1 of 9418



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy